2070014-88-7
2070014-88-7 結(jié)構(gòu)式
| 報(bào)價(jià)日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價(jià)格 |
| 2026/06/05 | HY-100347A | SRI-011381 hydrochloride | 2070014-88-7 | 1 mg | 336元 |
| 2026/06/05 | HY-100347A | SRI-011381 (hydrochloride) SRI-011381 hydrochloride | 2070014-88-7 | 5mg | 741元 |
| 2026/06/05 | HY-100347A | SRI-011381 (hydrochloride) SRI-011381 hydrochloride | 2070014-88-7 | 10mM * 1mLin DMSO | 815元 |
常見問題列表
TGF-beta
SRI-011381 hydrochloride promotes fibrillar Aβ clearance by macrophages, as demonstrated by the dose-dependent decreases of Aβ in the conditioned medium derived from compound-treated macrophages.
SRI-011381 hydrochloride (10 μM) eliminates Saikosaponin A (SSA, 30 μM)-induced protective effects on fibroblasts.
SRI-011381 hydrochloride protects mice against kainic acid-induced excitotoxicity and neurodegeneration.
SRI-011381 hydrochloride (10-75 mg/kg; p.o.; 14 days) results in significant changes in hematological endpoints, most notably reductions in red blood cells (RBCs), hematocrit and hemoglobin.
SRI-011381 hydrochloride (30 mg/kg; i.p.) activates TGF-β signaling in SBE-luciferase bioluminescent reporter mice.
SRI-011381 hydrochloride is rapidly absorbed after oral administration to FBV mice with an oral bioavailability of approximately 50%.
SRI-011381 hydrochloride reduces neurodegeneratio in APP751Lon, Swetransgenic mice.
| Animal Model: | FBV mice |
| Dosage: | 10 mg/kg, 30 mg/kg, 75 mg/kg |
| Administration: | Oral administration; 14 days |
| Result: | Resulted in significant changes in hematological endpoints, most notably reductions in red blood cells (RBCs), hematocrit and hemoglobin |